<DOC>
	<DOCNO>NCT01804166</DOCNO>
	<brief_summary>This study design collect tissue sample biopsy specimen use diagnose HSTCL , possible , obtain single blood sample , buccal swab sample bowel tissue sample . Samples obtain store sponsor future test . In addition , demographic clinical patient information collect . The study conduct North America . The study population include IBD patient North America HSTCL identify sponsor 's adverse event report system . Cases HSTCL identify postmarketing adverse event reporting ( eg , spontaneous report , report late phase clinical trial , report patient registry ) sponsor 's new ongoing clinical trial . Eligible enrollment male female patient age confirm diagnosis HSTCL . There study-related therapeutic intervention protocol restrict introduce therapeutic intervention , include medication . All patient continue manage personal physician . No healthy subject enrol study .</brief_summary>
	<brief_title>A Research Study Bank Samples Future Evaluation Identify Biomarkers That Predispose Crohn 's Disease Ulcerative Colitis Patients Develop Hepatosplenic T-Cell Lymphoma ( HSTCL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Patients Inflammatory Bowel Disease confirm diagnosis Hepatosplenic Tcell Lymphoma Be willing provide tumor biopsy sample study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Lymphoma , T-Cell , Peripheral , Infliximab , Golimumab , Remicade , Simponi , Ulcerative Colitis , Crohn 's Disease , Inflammatory Bowel Disease</keyword>
</DOC>